leisure time -WSS

leisure time

author：comprehensive 2025-10-02 22:57:37 - browse：5

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Laying a path for careers in science

explore

WSS

Readout Newsletter: Merck, Vertex, and Viking updates

Cholera vaccine supplies dangerously low, outbreaks surging

Study says nonprofit hospitals fall short in charity care spending

Merck drug for rare lung condition set for approval in U.S.

Pfizer is about to make a big push in cancer. Will investors listen?

Color Health wants to make cancer screenings convenient

explore

leisure time

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

Covid vaccine financial winners and losers, from Pfizer to Novavax

Dobbs anniversary: the lost opportunity of abortion as health care

Readout LOUD podcast: mifepristone case, GLP

https://cbu01.alicdn.com/img/ibank/2017/691/531/4439135196_1417957756.220x220xz.jpg

STAT Madness 2024: Meet the contenders

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: Merck, Vertex, and Viking updates

Tori Bowie and the unacceptable rates of Black maternal death

Why the world’s most expensive drug might be worth the price

Wikipedia

Primary care physicians play key roles in Alzheimer's management

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Virtual repurposing can help discover new uses for existing drugs

Roche subsidiary Foundation Medicine opens new headquarters

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

5 ways to address the shortage of health care workers

entertainment

explore

Wikipedia

focus